Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Blink® Tears eye drops
Blink Tears eye · 1 trial · 1 indication
High contrast bright illumination monocular logMAR (Logarithm of the Minimum Angle of Resolution) visual acuity was assessed at distance (4 meters) using ETDRS Charts, near (40 cm) and intermediate (64 cm) using reduced Guillon-Poling charts. A value of 0.0 logMAR indicated a Snellen vision of 20/20. Lower logMAR visual acuity values indicate better vision. The average logMAR visual acuity for each treatment was reported.
High contrast bright illumination monocular logMAR (Logarithm of the Minimum Angle of Resolution) visual acuity was assessed at distance (4 meters) using ETDRS Charts, near (40 cm) and intermediate (64 cm) using reduced Guillon-Poling charts. A value of 0.0 logMAR indicated a Snellen vision of 20/20. Lower logMAR visual acuity values indicate better vision. The average logMAR visual acuity for each treatment was reported.
| Arm | Type | Description |
|---|---|---|
| Test/Control | EXPERIMENTAL | Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the TEST lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the CONTROL lubricating eye drops will be instilled. |
| Control/Test | EXPERIMENTAL | Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the CONTROL lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the TEST lubricating eye drops will be instilled. |
| Name | Type | Description |
|---|---|---|
| Blink® Tears eye drops | DRUG | Control Drops |
| Investigational lipid eye drops | DRUG | Test Drops |
Inclusion Criteria: Potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions se...
Blink Tears eye is an investigational lipid-based lubricating eye drop developed by Johnson & Johnson (ticker JNJ). It is being studied in the ophthalmology therapeutic area for visual acuity, specifically in contact lens wearers. It is a small molecule product and remains in clinical development rather than being a marketed therapy.
Blink Tears eye is being studied for visual acuity in contact lens wearers. A completed Phase 1 clinical investigation evaluated visual acuity after instillation of the lipid-based lubricating eye drop. The study enrolled 32 participants in the United States and included healthy volunteers aged 18 years and older.
Blink Tears eye is developed by Johnson & Johnson, which trades under the ticker JNJ. The company is the sponsor associated with the clinical investigation of this lipid-based lubricating eye drop in contact lens wearers. No other developer or partner is identified for this asset.
Blink Tears eye is in Phase 1 clinical development. It is investigational and has not been established as an approved therapy. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
Blink Tears eye has been studied in one completed Phase 1 trial, NCT06131476, titled Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of a Lipid-Based Lubricating Eye Drop. The trial enrolled 32 participants in the United States, was randomized, double-blind, and controlled, and included healthy volunteers.
Yes. Blink Tears eye is also known as Blink Tears eye drops and Blink Tears eye Drops. These names refer to the same lipid-based lubricating eye drop developed by Johnson & Johnson for visual acuity in contact lens wearers, so searches using any of these names point to the same asset.